Posts by Sandra Ansanay-Alex
Acrotec appoints Didier Deltort as CEO
Microtech and Medtech company, Acrotec Group, has an new CEO. François Billig, CEO of the Acrotec Group (“Acrotec” or the “Group”), becomes non-executive Chairman. Didier Deltort, the new CEO, brings extensive international management experience in the fast-growing medical technology and additive manufacturing sectors as the Group enters a new phase of its development. Acrotec, a…
Read MoreVi Partners announces first close of its new CHF 150 million fund
The first close coincides with the 25th anniversary of Vi Partners, marking a quarter-century of continuous venture capital activity. Since its founding in 2001, Vi Partners has supported successive generations of entrepreneurs and contributed to the development of Switzerland as a leading hub for technology and healthcare innovation. Building on more than two decades of…
Read More4 New FIT Tech Grants To Life Sciences Projects
Four projects have received support from the Foundation for Innovation and Technology (FIT) in the form of CHF 100’000 Tech Grants: PreciMune and Tamaro Bioscience from CHUV, and Germion Therapeutics and Obstetrical Care Solutions from EPFL will be able to continue developing their technologies with the backing of the Foundation. PreciMune delivers superior immune profiling…
Read MoreNeurosoft Bioelectronics Shines at CES Las Vegas
Swiss neurotechnology startup Neurosoft Bioelectronics made a remarkable impression during CES 2026 in Las Vegas, capturing two major international awards and showcasing the global potential of next-generation brain–computer interfaces. At the Swisstech Deep Tech Pitch Battle, co-founder Ludovic Serex won 1st Prize in the AI Vertical, earning a $3,000 award and standing out among cutting-edge…
Read MoreDistalmotion Secures Investment From J&J
The Biopôle-based global MedTech company, which created the surgeon robot Dexter announced a strategic investment from Johnson & Johnson.
Read MoreFluoSphera secures CHF 1.15 million to advance animal-free drug discovery
University of Geneva spinoff FluoSphera announces a CHF 1.15 million in funding to make drug discovery faster, safer, and more human-relevant with its patented multi-tissue platform. The round was led by Soulmates Ventures and a Swiss business angel, with participation from IndieBio New York. The startup will use the funding to scale commercial collaborations, grow its…
Read MoreA New Centre to Advance Cardiovascular Research in Geneva
University of Geneva Faculty of Medicine has launched the Geneva Centre for Cardiac and Vascular Research (GCCVR).
Read MoreNourishAI, GenoRobotics and Infera Neuro Get Support from the EPFL Startup Launchpad
Three EPFL-born startups receive key funding to advance breakthrough technologies in health and biology.
Read MoreReverso Therapeutics Secures CHF 710,000 Innosuisse Grant
Reverso Therapeutics, a University of Geneva (UNIGE) pharmaceutical spin-off, and winner of the Bioinnovation Day Best Academic Project Award 2025, has been awarded a CHF 710,000 grant from Innosuisse to accelerate the development of its breakthrough reversible anticoagulant technology.
Read MoreAltiscreen receives CHF 150,000 from Venture Kick
The Jura-based medtech startup Altiscreen has obtained CHF 150,000 from Venture Kick to build a portable drug-testing solution that delivers clear results in just three minutes. Its device is designed to support roadside checks, workplace screening, and mobile healthcare teams that need reliable information on the spot. Every day, delayed or unreliable field drug tests…
Read More